Products

EFFECT OF B-LOCKTM THERAPY VS. HEPARIN
on Candida albicans biofilm formed on catheter in vivo (B)(A)

Scanning electron microscopy images of Candida albicans biofilms formed on the intraluminal surface of silicone catheters removed from infected rabbits treated with: (A) heparin lock solution and (B) B-LockTM solution.

Exclusive License to Antibiofilm Technology

The growing numbers of bacterial and fungal infections significantly contribute to morbidity and mortality as well as to the increased cost of hospital care. Most of the hospital-acquired bacterial and fungal infections result from invasive supportive measures such as the placement of catheters. These conditions, referred to as catheter-related bloodstream infection (CRBI), are difficult to prevent due to formation of biofilm in the catheter lumen.

Great Lakes Pharmaceuticals acquired exclusive license to antibiofilm technology from University of Texas M.D. Anderson Cancer Center and Wake Forest University. Based on the licensed technology, the company has developed a device/drug combination product, B-Lock™, capable of effective prevention of CRBI. In addition to its antimicrobial value, B-Lock™ solution has the added benefit of antithrombotic properties.

Antimicrobial Activity

B-Lock™’s spectrum of antimicrobial activity includes all bacterial and fungal pathogens associated with CRBI. Antithrombotic effectiveness equals heparin. With the use of B-Lock™, there is no need for application of heparin lock solution.